ABVC (ABVC BioPharma, Inc.) Company Net Assets

ABVC BioPharma (ABVC) extraction capacities and contract lines are functioning effectively, ensuring timely equipment calibration for current tests. The company generates revenue through the licensing of innovations and the study of phytopharmaceuticals against neurological and oncological pathologies, with the indicator standing at 0.01. Serving as an assessment tool, this price chart complements data on hubs in the US and Taiwan, where production scaling has been outsourced to external CDMO partners.

Book value capitalization is calculated as the difference between total assets and liabilities, reflecting the actual value of equity without market noise. For ABVC BioPharma, the total book capitalization figure demonstrates the efficiency of monetizing intellectual property through licensing agreements with Asian partners, replacing costly acquisitions with organic growth of net assets.